Algernon Pharmaceuticals Inc.
AGN
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -272.30K | -377.30K | -1.97M | -3.86M | -4.03M |
| Total Depreciation and Amortization | 18.10K | 19.50K | 25.60K | 30.60K | 34.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.23M | -1.19M | 60.60K | 1.57M | 1.77M |
| Change in Net Operating Assets | -643.20K | -445.60K | -77.40K | 1.07M | 894.10K |
| Cash from Operations | -2.13M | -1.99M | -1.96M | -1.19M | -1.33M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.67M | 1.67M | 1.67M | -41.30K | -30.90K |
| Cash from Investing | 1.67M | 1.67M | 1.67M | -41.30K | -30.90K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 614.90K | 614.70K | 370.80K | 1.42M | 1.16M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 286.50K | 286.50K | 171.40K | 91.20K | 69.50K |
| Cash from Financing | 662.00K | 661.80K | 405.20K | 1.12M | 907.10K |
| Foreign Exchange rate Adjustments | 2.80K | -200.00 | 3.30K | -300.00 | -1.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 210.00K | 345.90K | 123.60K | -110.20K | -459.50K |